GlaxoSmithKline has agreed to plead guilty and pay a massive fine totaling $750 million to the federal government and the states to resolve allegations that the company caused false claims to be submitted to govern ment health care programs for certain quantities of adulterated Kyrtil, Bactroban, Paxil CR and Avandamet -- were made at its SB Pharmo Puerto Rico Inc’s plant and would pay about $750 million to resolve the allegations.

Of the $750 million, Glaxo will pay $600 million to settle allegations that, because the drugs were adulterated, false claims for reimbursement were submitted to government healthcare programs. The drugs -- the anti- depressant Paxil CR and diabetes ointment Bactroban, anti-de pressant Kyrtil, skin ointment Bactroban, anti-diabetes drug Avandamet -- were made at the plant between 2001 and 2005.

The company was accused in July it reached an agreement in principle relating to quality problems at its SB Pharmo Puerto Rico Inc’s plant and would pay about $750 million to resolve the allegations. Of the $750 million, Glaxo will pay $600 million to settle allegations that, because the drugs were adulterated, false claims for reimbursement were submitted to government healthcare programs. The drugs -- the antidepressant Paxil CR and diabetes ointment Bactroban, anti-depressant Kyrtil, skin ointment Bactroban, anti-diabetes drug Avandamet -- were made at the plant between 2001 and 2005.

The company was accused of failing to ensure the drugs were properly manufactured at the plant and thus effective, according to the Justice Department.

Under the plea agreement, SB Pharmo Puerto Rico Inc’s plant and would pay about $750 million to resolve the allegations. Of the $750 million, Glaxo will pay $600 million to settle allegations that, because the drugs were adulterated, false claims for reimbursement were submitted to government healthcare programs.

The drugs -- the antidepressant Paxil CR and diabetes ointment Bactroban, anti-depressant Kyrtil, skin ointment Bactroban, anti-diabetes drug Avandamet -- were made at the plant between 2001 and 2005.

The company was accused in July it reached an agreement in principle relating to quality problems at its SB Pharmo Puerto Rico Inc’s plant and would pay about $750 million to resolve the allegations.